Loading...
•
Dec 31, 2020
Arbutus Q4 2020 Earnings Report
Arbutus reported its Q4 2020 financial results and provided a corporate update.
Key Takeaways
Arbutus Biopharma Corporation reported its fourth quarter and year-end 2020 financial results. The company's lead compound, AB-729, showed potential as a cornerstone drug in future HBV combination regimens. Several Phase 2 proof-of-concept combination clinical trials are expected to initiate this year. Arbutus expects a net cash burn between $70 to $75 million in 2021 and believes its cash runway extends through the third quarter of 2022.
AB-729 demonstrates robust declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV).
Reductions in HBsAg support a potential dosing schedule for AB-729 as infrequently as every 8 to 12 weeks.
Several AB-729 Phase 2 proof-of-concept combination clinical trials are expected to initiate this year.
AB-836, Arbutus’ proprietary oral capsid inhibitor, on track to begin a Phase 1a/1b clinical trial in the first half of 2021.
Forward Guidance
Arbutus expects a net cash burn between $70 to $75 million in 2021 and therefore the Company believes its cash runway extends through the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...